Daily PubMed evidence board
Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence.
This systematic review pooled randomized trials and real-world studies to evaluate monoclonal antibodies that block calcitonin gene-related peptide (CGRP)…
Signal score51Research triage score
CertaintyLowVerify in full text
PMID42262668Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review pooled randomized trials and real-world studies to evaluate monoclonal antibodies that block calcitonin gene-related peptide (CGRP) or its receptor for preventing chronic migraine, a disabling condition with ≥15 headache days per month. The authors report consistent reductions in migraine frequency, improved ≥50% responder rates, and generally favorable safety across trial and real-world settings. However, differences in how studies measured outcomes (monthly migraine days versus monthly headache days) and study designs create heterogeneity. The review concludes CGRP-targeted monoclonal antibodies are effective and well tolerated for chronic migraine prevention but calls for more research on long-term outcomes and standardized measures.
Why it matters
- Addresses prevention of chronic migraine (≥15 headache days/month, ≥8 migrainous) where existing preventive options often have limited efficacy and tolerability.
- Assesses CGRP-targeted monoclonal antibodies, a mechanism-based class with potential to reduce monthly migraine/headache days and increase ≥50% responder rates in chronic migraine patients.
- Integrates randomized and real-world evidence, which is relevant for both regulatory/clinical guideline decision-making and real-world adoption in treatment-resistant or heterogeneous patient populations.
Primary outcomes
- Efficacy, safety, and clinical relevance of CGRP-targeted monoclonal antibodies in the prevention of chronic migraine (as reported across included RCTs and real-world studies).
Effect summary
Abstract-reported signal: CGRP-targeted monoclonal antibodies consistently reduced migraine frequency, improved ≥50% responder rates, and had favorable safety profiles across randomized trials and real-world studies; heterogeneity exists due to varying outcome definitions and study designs.
Benefit-cost lens
| Quick take | Promising clinical effectiveness and tolerability signal from RCTs and real-world studies, but benefit-cost claims need absolute effect sizes, baseline risk, and cost/implementation inputs before any adoption decision. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based only on PubMed metadata and abstract; full-text review needed to extract quantitative effect estimates, heterogeneity, long-term outcomes, and precise safety data. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Higher uncertainty |
| Notes | Assessment based only on the abstract and metadata. While RCTs provide higher internal validity, integration with heterogeneous real-world observational studies increases overall uncertainty. Full-text review needed for formal risk-of-bias appraisal (study selection, outcomes, funding, selective reporting). |
Harms, equity, conflicts & implementation
| Implementation | Full-text extraction of quantitative effects, safety event rates, eligible population definition, cost data, reimbursement pathways, and operational feasibility; stakeholder (neurology/pharmacy/payers) consultation recommended before policy or formulary decisions. |
|---|---|
| Equity impact | Unclear from abstract; equity implications depend on access, affordability, and whether subgroup analyses (e.g., by socioeconomic status, geography) reveal differential effectiveness or harms in the full text. |
| Harms | Abstract states favorable safety profiles but does not detail adverse event types or rates. Full-text review required to quantify harms, rare events, and long-term safety. |
| Registration | CRD420261284751 |
| Replication | Unknown from automated PubMed triage; review integrates multiple studies but replication of specific effects requires inspecting included studies. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.